ATH-409 / Atheron Therapeutics - LARVOL DELTA

Identification of a highly selective ITK inhibitor which promotes Th1 differentiation and alleviates T cell exhaustion in vitro and in vivo (AACR 2026) - "Furthermore, when ATH-409 is combined with PD-1 antibody and CTLA-4 antibody, the inhibitory effect on CT26 tumors is further enhanced. Analysis of tumor-infiltrating lymphocytes (TILs) reveals that under the combination treatment, the proportion of Th1 cells in tumors increases and T cell exhaustion is alleviated, which is consistent with the phenomena observed in in vitro experiments."

Preclinical • Oncology • IL2